R
Ronald N. Jones
Researcher at Tufts University
Publications - 1169
Citations - 57539
Ronald N. Jones is an academic researcher from Tufts University. The author has contributed to research in topics: Broth microdilution & Antimicrobial. The author has an hindex of 109, co-authored 1169 publications receiving 54206 citations. Previous affiliations of Ronald N. Jones include NewYork–Presbyterian Hospital & University of Iowa.
Papers
More filters
Journal ArticleDOI
Nosocomial Bloodstream Infections in United States Hospitals: A Three-Year Analysis
Michael B. Edmond,Sarah E. Wallace,Donna K. McClish,Michael A. Pfaller,Ronald N. Jones,Richard P. Wenzel +5 more
TL;DR: Concurrent surveillance for nosocomial bloodstream infections at 49 hospitals over a 3-year period detected >10,000 infections, and coagulase-negative staphylococci were the most common pathogens on all clinical services except obstetrics, where Escherichia coli was most common.
Journal ArticleDOI
Does the use of antibiotics in food animals pose a risk to human health? A critical review of published data
Ian R. Phillips,Mark Casewell,Tony Cox,Brad de Groot,Christian Friis,Ronald N. Jones,Charles H. Nightingale,Rodney Preston,John Waddell +8 more
TL;DR: The application of the 'precautionary principle' is a non-scientific approach that assumes that risk assessments will be carried out, and anti-Gram-positive growth promoters would be expected to have little effect on most Gram-negative organisms.
Journal ArticleDOI
10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher,George H. Talbot,Daniel K. Benjamin,Daniel K. Benjamin,John S. Bradley,John S. Bradley,Robert Guidos,Ronald N. Jones,Barbara E. Murray,Robert A. Bonomo,David N. Gilbert,David N. Gilbert +11 more
TL;DR: This survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive.
Journal ArticleDOI
Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
TL;DR: The empirical treatment of HABP and VABP due to prevailing bacterial causes and emerging drug resistance has become more challenging and requires use of multidrug empirical treatment regimens for routine clinical practice.
Journal ArticleDOI
Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
TL;DR: Overall, U.S. isolates were considerably more resistant than those from Canada, and distinct differences were noted in the antimicrobial susceptibilities of several pathogens.